We are developing patient-derived induced pluripotent stem cell (iPSC) lines along with matched isogenic controls. These patient-derived lines will represent a range of FOXP1 mutation types, including missense, nonsense, frameshift (insertions/deletions), and intronic variants.

Patient-derived induced pluripotent stem cell (iPSC) lines are lab-grown cells created from a patient’s own blood or skin. These cells are reprogrammed to behave like early stem cells, which means they can later be differentiated into many other cell types. This makes them powerful tools for building cellular models used in experiments, ranging from basic neuronal systems to more complex brain organoids.

Because these cells carry the patient’s exact genetic code—including their FOXP1 mutation—they allow researchers to study FOXP1 syndrome in a human cellular model, rather than relying solely on animal models. Isogenic controls are genetically matched versions of these patient-derived lines in which the FOXP1 mutation has been precisely corrected using gene editing. These controls provide a critical comparison, showing how the same cells behave with identical genetics except for the FOXP1 mutation.

iPSC line development will start in early 2026.

We are creating patient-derived iPSCs in collaboration with leading CROs specializing in stem cell model development.

For drug development, iPSC models help identify promising treatments, test whether therapies correct disease-related changes, and reduce risk by showing early evidence that a drug could work in patients. Using isogenic controls allows researchers to be confident that any differences they see are due to the mutation itself and not unrelated genetic variation.